Australian Guidelines for ADHD Treatment in Adults

Pharmacological Treatment Options

Methylphenidate formulations (short-acting, intermediate-acting, and long-acting) are recommended as first-line pharmacological treatment for adults with ADHD due to their strong evidence of efficacy, as suggested by the American Academy of Pediatrics 1, 2
Atomoxetine (Strattera) is recommended as a non-stimulant option when stimulants are ineffective, not tolerated, or contraindicated, with robust evidence of efficacy from the American Academy of Pediatrics 1, 2, 3
Extended-release guanfacine (Intuniv) and extended-release clonidine (Kapvay) are also recommended as non-stimulant options, with evidence of efficacy from the American Academy of Pediatrics 1, 2, 4

Psychoeducation about ADHD is recommended to improve understanding and management of the condition, as suggested by the Journal of Child Psychology and Psychiatry and Allied Disciplines 5
Recovery-focused care that considers the individual's values, feelings, goals, and strengths is also recommended, with evidence from the Journal of Child Psychology and Psychiatry and Allied Disciplines 5

Confirming diagnosis using appropriate diagnostic criteria and assessment tools is essential, as recommended by the American Academy of Pediatrics 3
Initiating pharmacological treatment with stimulants (methylphenidate or amphetamine derivatives) is recommended if indicated, with evidence of efficacy from the American Academy of Pediatrics 1, 2
Implementing non-pharmacological interventions concurrently with medication is also recommended, with evidence from the Journal of Child Psychology and Psychiatry and Allied Disciplines 5
Regular monitoring of treatment efficacy, side effects, and functional outcomes is necessary, with evidence from the American Academy of Pediatrics 3

The National Institute for Health and Care Excellence (NICE) guidelines recommend switching to Lisdexamfetamine (LDX) after a 6-week trial of methylphenidate at adequate dose without sufficient benefit, as LDX is a prodrug of dextroamphetamine with lower abuse potential 6, 7
Regional guidelines vary, with Western guidelines typically recommending stimulants as first-line, while some Asian countries recommend non-stimulants (atomoxetine or guanfacine) as first-line due to concerns about stimulant abuse 6, 7, 8

Atomoxetine is the primary second-line option when stimulants fail after adequate optimization, with robust evidence of efficacy in adults with ADHD 6, 7

The American College of Cardiology recommends careful assessment of cardiac disease risk before initiating pharmacotherapy for ADHD, including evaluation of structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, or coronary artery disease, although no specific citation is provided in the given text, the general principle is supported by 6, 7